Hairy cell leukemia (HCL) is a rare lymphoproliferative disease with specific morphologic and molecular features and excellent prognosis. Although high rate of complete response (CR) has been reported after treatment with purine analogs, expecially cladribine (2CDA), relapse may occur during follow-up. The aim of the study is to review the efficacy, safety, long term remission rate and overall survival (OS) in those patients (pts) that received 2CDA as first line treatment.
Multicenter Long Term Follow-up in Hairy Cell Leukemia Patients Treated with Cladribine: A Thirty-Year Experience / Criscuolo, Marianna; Broccoli, Alessandro; Galli, Eugenio; Piciocchi, Alfonso; Maraglino, Alessio; Anastasia, Antonella; Annibali, Ombretta; Cantonetti, Maria; De Luca, Maria Lucia; Fianchi, Luana; Frustaci, Annamaria; Galli, Elettra; Guarnera, Luca; Kovalchuk, Sofia; Marchesi, Francesco; Motta, Marina; Nizzoli, Maria Elena; Offidani, Massimo; Orsucci, Lorella; Spolzino, Angelica; Stelitano, Caterina; Storti, Sergio; Tedeschi, Alessandra; Trentin, Livio; Varettoni, Marzia; Visentin, Andrea; Volpetti, Stefano; Falini, Brunangelo; Pulsoni, Alessandro; Tiacci, Enrico; Zinzani, Pier Luigi; Pagano, Livio. - In: BLOOD. - ISSN 0006-4971. - ELETTRONICO. - 136:(2020), pp. 32-33. [10.1182/blood-2020-136633]
Multicenter Long Term Follow-up in Hairy Cell Leukemia Patients Treated with Cladribine: A Thirty-Year Experience
Galli, Elettra
;Kovalchuk, Sofia
;
2020
Abstract
Hairy cell leukemia (HCL) is a rare lymphoproliferative disease with specific morphologic and molecular features and excellent prognosis. Although high rate of complete response (CR) has been reported after treatment with purine analogs, expecially cladribine (2CDA), relapse may occur during follow-up. The aim of the study is to review the efficacy, safety, long term remission rate and overall survival (OS) in those patients (pts) that received 2CDA as first line treatment.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
